Sphingosine 1-Phosphate Receptor 4 Expression in Colorectal Cancer Patients

Suchittra SAMUHASANEETO, Suthiporn PROMAGSORN, Chuchard PUNSAWAD

Abstract


The aim of this study was to investigate the expression of S1PR4 in colorectal cancer and its correlation with clinicopathologic characteristics. Paraffin-embedded colorectal cancer samples and matched adjacent normal tissues were collected from 32 patients at Maharat Nakhon Si Thammarat Hospital. The expression of SphK1 and S1PR4 in colorectal cancer and matched normal tissues were determined by immunohistochemistry and compared with the clinicopathologic characteristics for each of the 32 colorectal cancer patients. There were 20 males (62.50 %) and 12 (37.50 %) females. The mean age was 59.66±12.66 years. The majority of tumors were moderately differentiated (62.50 %). A high level of SphK1 and S1PR4 protein expression was observed in tumor samples compared with adjacent normal mucosa (P = 0.005 and P = 0.02, respectively). The neoplastic cells showed positive cytoplasmic staining expression for both SphK1 and S1PR4 proteins. The distribution of these 2 proteins in colorectal cancer patients showed that neither were significantly correlated to clinicopathologic features such as sex, age, pathological stage, T stage, N stage, M stage, tumor differentiation, tumor location or tumor size. It was found that S1PR4 was overexpressed in colorectal cancer and may influence tumor progression, however, there was no correlation between S1PR4 expression and clinicopathologic characteristics.


Keywords


Sphingosine 1-phosphate receptor 4, Sphingosine-1-phosphate, sphingosine kinase 1, colorectal cancer

Full Text:

PDF

References


J Ferlay, I Soerjomataram, M Ervik, R Dikshit, S Eser, C Mathers, D Forman and F Bray. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015; 136, E359-E386.

CJ Chen, SL You, LH Lin, WL Hsu and YW Yang. Cancer epidemiology and cancer control in Taiwan: a brief review. Jpn. J. Clin. Oncol. 2002; 32, S66-S81.

JJ Sung, JY Lau, KL Goh and WK Leung. Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet. Oncol. 2005; 6, 871-6.

J Ferlay, HR Shin, F Bray, D Forman, C Mathers and DM Parkin. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127, 2893-917.

W Imsamram, A Chaiwerawattana, S Wiangnon, D Pongnikorn, K Suwanrungrung, S Sangrajrang and R Buasom. Cancer in Thailand. Vol VIII. New Thammada Press, Bangkok, 2015, p. 50.

CE DeSantis, CC Lin, AB Mariotto, RL Siegel, KD Stein, JL Kramer, R Alteri, AS Robbins and A Jemal. Cancer treatment and survivorship statistics, 2014. CA. Cancer J. Clin. 2014; 64, 252-71.

S Pyne, SC Lee, J Long and NJ Pyne. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate in health and disease. Cell Signal 2009; 21, 14-21.

J Ohotski, JS Long, C Orange, B Elsberger, E Mallon, J Doughty, S Pyne, NJ Pyne and J Edwards. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associates with outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 2012; 106, 1453-9.

KR Johnson, KY Johnson, HG Crellin, B Ogretmen, AM Boylan, RA Harley and LM Obeid. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J. Histochem. Cytochem. 2005; 53, 1159-66.

G Liu, H Zheng, Z Zhang, Z Wu, H Xiong, J Li and L Song. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer 2010; 10, 495-506.

J Pan, YF Tao, Z Zhou, BR Cao, SY Wu, YL Zhang, J Wang, GL Lou, Z Li, X Feng and J Ni. A novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J. Trans. Med. 2011; 9, 157-71.

T Kawamori, T Kaneshiro, M Okumura, S Maalouf, A Uflacker, J Bielawski, YA Hannun and LM Obeid. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J. 2009; 23, 405-14.

SQ Liu, YJ Su, MB Qin, YB Mao, JA Huang and GD Tang. Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules. Int. J. Oncol. 2013; 42, 617-26.

SB Edge, DR Byrd, CC Compton, AG Fritz, FL Greene and A Trotti. AJCC Cancer Staging Handbook. 7th ed. Lippinocott Raven Publishers, Philadelphia, 2010, p. 173-4.

JP Spano, C Lagorce, D Atlan, G Milano, J Domont, R Benamouzig, A Attar, J Benichou, A Martin, JF Morere, M Raphael, F Penault-Llorca, JL Breau , R Fagard, D Khayat and P Wind. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005; 16, 102-8.

MH Chen, CC Yen, CT Cheng, RC Wu, SC Huang, CS Yu, YH Chung, CY Liu, PMH Chang, Y Chao, MH Chen, YF Chen, KC Chiang, TS Yeh, TC Chen, CYF Huang and CN Yeh. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget 2015; 6, 23594-608.

HS Kim, G Yoon, JY Ryu, YJ Cho, JJ Choi, YY Lee, TJ Kim, CH Choi, SY Song, BG Kim, DS Bae and JW Lee. Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget 2015; 6, 26746-56.

S Pyne, J Edwards, J Ohotski and NJ Pyne. Sphingosine 1-phosphate receptors and sphingosine kinase 1: Novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front. Oncol. 2012; 2, 1-5.

Y Xu, B Dong, J Huang, W Kong, W Xue, Y Zhu, J Zhang and Y Huang. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Oncotarget 2016; 7, 3233-44.

W Li, CP Yu, JT Xia, L Zhang, GX Weng, HQ Zheng, QL Kong, LJ Hu, MS Zeng, YX Zeng, M Li, J Li and LB Song. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res. 2009; 15, 1393-9.

SQ Liu, JA Huang, MB Qin, YJ Su, MY Lai, HX Jiang and GD Tang. Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulation the production of MMP-2/9 and uPA via MAPK pathways. Int. J. Colorectal Dis. 2012; 27, 1569-78.

YJ Su, JA Huang, SQ Liu, JX Huang, YY Zhong, GD Tang and HX Jiang. The expression and clinical significance of SphK1 and nuclear factor-kB p65 in human colon carninoma. Zhonghua. Nei. Ke. Za. Zhi. 2012; 51, 220-4.

J Long, Y Xie, J Yin, W Lu and S Fang. SphK1 promotes tumor cell migration and invasion in colorectal cancer. Tumor. Biol. 2016; 37, 6831-6.

T Ju, D Gao and ZY Fang. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem. Biophys. Res. Commun. 2016; 470, 729-34.

SSL Tan, LW Khin, L Wong, B Yan, CW Ong, A Datta, M Salto-Tellez, Y Lam Y and CT Yap. Sphingosine kinase1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in south Asian population. Clin. Trans. Gastroenterol. 2014; 5, e51.

JS Long, Y Fujiwara, J Edwards, CL Tannahill, G Tigyi, S Pyne and NJ Pyne. Sphingosine 1-phosphate receptor 4 use HER2(ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 2010; 285, 35957-66.


Refbacks

  • There are currently no refbacks.




http://wjst.wu.ac.th/public/site/images/admin/image012_400

Online ISSN: 2228-835X

http://wjst.wu.ac.th

Last updated: 20 June 2019